Seres Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Seres Therapeutics, Inc. (MCRB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $92.07 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $96.24, a 0.82% increase year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $95.46, a 968.98% increase year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.93, a 14.63% decline year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $10.46, a 2.65% increase year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $114.77, a 1442.61% increase from fiscal 2024.
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $7.44.
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $10.62, a 12.88% decline from fiscal 2021.
- Seres Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $12.19, a 16.10% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $92.07 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $96.24 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $114.77 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $126.37 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $112.31 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $95.46 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $7.44 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $7.55 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $8.56 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $8.93 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $8.30 8-K · filed 2024-08-15 | |||
| 2023-06-30 | $9.39 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $10.46 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $10.62 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $10.48 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | $10.41 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $10.19 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $12.19 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $12.11 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $12.78 10-Q · filed 2021-08-03 | |||
| 2021-03-31 | $23.58 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $10.50 10-K · filed 2021-03-02 | |||
| 2020-09-30 | $10.66 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $10.91 10-Q · filed 2020-07-28 | |||
| 2020-03-31 | $8.62 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $12.82 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $12.69 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $12.08 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $12.70 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $15.99 10-K · filed 2019-03-06 | |||
| 2018-09-30 | $16.96 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $16.95 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $17.60 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $21.07 10-K · filed 2018-03-08 | |||
| 2017-09-30 | $20.66 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $20.18 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $22.73 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $24.93 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $22.25 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | $13.48 10-Q · filed 2016-08-11 | |||
| 2015-12-31 | $5.04 10-K · filed 2016-03-14 | |||
| 2015-09-30 | $5.04 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $1.62 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |